Last reviewed · How we verify
SSP-004184
At a glance
| Generic name | SSP-004184 |
|---|---|
| Also known as | SPD602, FBS0701 |
| Sponsor | Shire |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Relative Bioavailability Study of SSP-004184AQ (Magnesium Salt) and SSP-004184SS (Disodium Salt) (PHASE1)
- Study of SSP-004184 (SPD602) in Healthy Adults and Subjects With Impaired Liver Function (PHASE1)
- Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using FBS0701 (SSP-004184) (PHASE2)
- Pharmacokinetics of SSP-004184 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy (PHASE2)
- Pharmacokinetic Interaction Between SSP-004184 (SPD602) and Midazolam in Healthy Adult Subjects (PHASE1)
- AME (Absorption, Metabolism, and Excretion) of Radiolabeled SSP-004184 (PHASE1)
- Effect of SSP-004184 (SPD602) on the Pharmacokinetics of Simvastatin in Healthy Adult Subjects (PHASE1)
- Safety, Efficacy and Pharmacokinetics of an Oral Iron Chelator Given for a Year to Pediatric Patients With Iron Overload (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SSP-004184 CI brief — competitive landscape report
- SSP-004184 updates RSS · CI watch RSS
- Shire portfolio CI